Aptevo Therapeutics Inc. (APVO)

$ 17.93
-0.4 (-2.19%)
Symbol APVO
Price $ 17.93
Beta 7.145
Volume Avg. 0.08M
Market Cap 0.08B
Shares () -
52 Week Range 6.17-60.0
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -219.84% Strong Sell
ROA -30.34% Strong Sell
Operating Margin -
Debt / Equity 554.54% Strong Buy
P/E -
P/B 7.52 Strong Buy


Consensus EPS

Upgrades & Downgrades


Mr. Marvin L. White
Nasdaq Global Select

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.